Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.63 |
| ▸ | NPY2R | P49146 | 1/20 | 0.63 |
| ▸ | NPY4R | P50391 | 1/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.62 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.62 |
| ▸ | CCKBR | P32239 | 1/20 | 0.62 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683247 | 0.88 | GLP1R (0.65) | GLP1RECE1MUS81NPY1RNPY2R | |
| Dermaseptin S1 SCHEMBL30063560 | 0.88 | PTH1R (0.68) | GLP1RECE1MUS81PTH1RCCKBR | |
| SCHEMBL29408638 | 0.87 | GHSR (0.62) | — | |
| SCHEMBL29370374 | 0.87 | GLP1R (0.71) | GLP1RECE1MUS81NPY1RNPY2R | |
| SCHEMBL29358003 | 0.87 | NR3C1 (0.66) | GLP1RECE1MUS81NR3C1 | |
| SCHEMBL29534976 | 0.87 | GLP1R (0.60) | GLP1RCCKBR | |
| SCHEMBL31578362 | 0.86 | GLP1R (0.73) | GLP1RECE1MUS81NR3C1PTH1R | |
| SCHEMBL31060658 | 0.85 | GLP1R (0.89) | GLP1RECE1MUS81NR3C1PTH1R | |
| Teduglutide SCHEMBL20898050 | 0.85 | GLP1R (0.82) | GLP1RECE1MUS81NR3C1PTH1R | |
| SCHEMBL29748897 | 0.85 | GLP1R (0.61) | GLP1RECE1MUS81PTH1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747274-A2 | PROTEIN-BASED DELIVERY SYSTEM | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2025019713-A2 | PROTEIN-BASED DELIVERY SYSTEM | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-01-23 | — | — | WO | claimed |
| CN-116179609-A | Method for improving transfection efficiency of membrane-permeable polypeptide gene | 中山大学附属第七医院(深圳) | 2023-05-30 | — | — | CN | claimed |
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | claimed |
| EP-4747274-A2 | PROTEIN-BASED DELIVERY SYSTEM | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122070299-A | Cell penetrating agent and use thereof | 普罗塞纳生物科学有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3574909-B1 | POLYELECTROLYTE MULTILAYER COMPRISING SILVER FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260022349-A1 | ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | MASSACHUSETTS GEN HOSPITAL (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250375394-A1 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | ABBOTT NICHOLAS L (US) | 2025-12-11 | — | — | US | disclosed |
| US-12409247-B2 | Methods and compositions for wound healing | IMBED BIOSCIENCES INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12404525-B2 | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells | THE GENERAL HOSPITAL CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4001295-A1 | PEPTIDE THERAPEUTICS FOR AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES | Genesen Co., Ltd. (KR) | 2022-05-25 | — | — | EP | disclosed |
| EP-3995158-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | Imbed Biosciences, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11325955-B2 | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3982989-A1 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | The General Hospital Corporation (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3978605-A1 | ANTIMICROBIAL AGENTS AGAINST SALMONELLA BACTERIA | Lysando AG (LI) | 2022-04-06 | — | — | EP | disclosed |
| EP-3541406-B1 | NEW ANTIMICROBIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | LYSANDO AG (LI) | 2022-03-16 | — | — | EP | disclosed |
| US-20220064623-A1 | ENDOLYSIN VARIANT | SASINAPAS CO., LTD. (TH) | 2022-03-03 | — | — | US | disclosed |
| WO-2022020800-A2 | ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022349-A1 | ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | PLTP, TMIGD3, APOL1 | GLP1R 2734/4885ECE1 2908/4885MUS81 1537/4885 |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | PCNA, ARG1, PLOD3 | GLP1R 4075/4885ECE1 3033/4885MUS81 2607/4885 |
| US-11325955-B2 | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections | MME, CLPP, VIP | GLP1R 347/4885ECE1 976/4885MUS81 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.